Horizon Pharma signs $1.1bn deal to buy Hyperion
This article was originally published in Scrip
Dublin-based Horizon Pharma is to acquire Hyperion Therapeutics in an all-cash deal worth $1.1bn or $46.00 per share, about a 35% premium to its average share price for the past 60 days.
You may also be interested in...
Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.